A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Фаза 2
Идёт, набор закрыт
NCT02623972
| Заболевание | Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Dana-Farber Cancer Institute |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 22 участн. |
|---|
| Вмешательство | Eribulin, Adriamycin, Cyclophosphamide |
|---|
| Дата начала | 26.02.2016 |
|---|
| Дата завершения | 05.2021 |
|---|
| Публикация результатов | 28.12.2022 |
|---|
Кратко
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
Pathologic Complete Response Rate
Assessed after preoperative therapy with either 4 cycles of eribulin mesylate (3 wks) followed by 4 cycles of doxorubicin/cyclophosphamide (2 wks) or after 4 cycles of AC(2 wks) followed by 4 cycles of eribulin(3 wks). As such up to 20 weeks. · percentage of participants
| Arm A: Eribulin Followed by AC | 6.25 percentage of participants |
|---|
| Arm B: AC Followed by Eribulin | 0 percentage of participants |
|---|
| Pathelogic Complete Response Rate | 30 |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.